Cambridge Investment Research Advisors’s Cardlytics CDLX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27K	Buy	+2,575	New	+$25.1K	﹤0.01%	3885

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Cambridge Investment Research Advisors's CDLX Position: Q1 2026 in Review

Cambridge Investment Research Advisors opened a new position in Cardlytics (CDLX) in Q1 2026: 2,575 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #3885 among its holdings.

58 funds tracked by Wall St. Rank hold CDLX as of Q1 2026.

Cambridge Investment Research Advisors held 2,575 shares of Cardlytics worth $27K as of Q1 2026.
Cardlytics was a new Cambridge Investment Research Advisors position in Q1 2026.
Cardlytics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3885 holding.
58 funds tracked by Wall St. Rank held Cardlytics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.